文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

作者信息

Khadka Roman H, Sakemura Reona, Kenderian Saad S, Johnson Aaron J

机构信息

Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Department of Immunology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

出版信息

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4.

DOI:10.2217/imt-2019-0074
PMID:31161844
Abstract
摘要

相似文献

[1]
Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Immunotherapy. 2019-7

[2]
Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol. 2019-3-18

[3]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

[4]
Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment.

Int J Mol Sci. 2021-7-17

[5]
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.

Biol Blood Marrow Transplant. 2018-12-23

[6]
Management Principles Associated With Cytokine Release Syndrome.

Semin Oncol Nurs. 2019-8-31

[7]
Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.

Clin Cancer Res. 2018-10-15

[8]
T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.

Heart Fail Clin. 2022-7

[9]
Cytokine release syndrome and cancer immunotherapies - historical challenges and promising futures.

Front Immunol. 2023

[10]
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?

J Immunother Cancer. 2020-5

引用本文的文献

[1]
Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation.

J Transl Med. 2025-7-25

[2]
Combined IVIG and High-Dose Systemic Corticosteroids for the Management of Pembrolizumab-Induced Cytokine Release Syndrome in Lung Adenocarcinoma.

Respirol Case Rep. 2025-5-19

[3]
CAR-T therapy dilemma and innovative design strategies for next generation.

Cell Death Dis. 2025-3-27

[4]
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.

Clin Pharmacokinet. 2024-12

[5]
PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies.

Mol Imaging. 2024

[6]
Harnessing the cGAS-STING pathway to potentiate radiation therapy: current approaches and future directions.

Front Pharmacol. 2024-4-10

[7]
A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.

Cancer Immunol Immunother. 2024-4-20

[8]
Autoimmune Limbic Encephalitis in Patients with Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide.

Cells. 2023-8-11

[9]
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors.

Nat Cancer. 2023-4

[10]
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model.

J Vis Exp. 2023-2-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索